In a nutshell This clinical trial is evaluating the safety and effectiveness of an experimental treatment, BXCL701, in combination with pembrolizumab (Keytruda) for people with small cell neuroendocrine prostate cancer (SCNPCa). The main outcome to be measured will be the response rate to the study treatment. The details Prostate cancer is the...
Read More
Barry Nelson, Patient Advisor at Brigham and Women’s Hospital Center for Patients and Families participated in a webinar on January 11 organized by The Center for Health Education Research Service in Boston, Massachusetts. [1] During the webinar, Nelson described his experience as a cancer survivor. “I was diagnosed with advanced lung cancer...
Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...
Read More
In a nutshell This trial is looking to examine the use of radiation on a shorter schedule of 5 days in a row is a safe and effective way to prevent breast cancer (BC) from coming back in people who have had a mastectomy (surgical removal of the breast). The main outcomes that are to be measured are local and regional disease recurrence. This trial is to...
Read More
In a nutshell This trial is comparing conventional physical therapy, a powered exoskeleton (PE), and a combination of both treatments for stroke survivors. The main outcome will be the change in walking and balance before and after treatment. This trial will be conducted in California, US. The details A stroke happens when the blood flow to the brain...
Read More
In a nutshell This trial is aiming to examine the effectiveness of combination therapy with venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Ozurdex) with or without bortezomib (Velcade) for unresponsive or relapsed multiple myeloma (MM). The main outcome that is to be measured is the response rate, time to response,...
Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including lung cancer. The main outcomes to be measured are drug toxicity and the response rate of patients to the drug. This trial is being carried out in...
Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including prostate cancer. The main outcomes to be measured are drug toxicity and the response rate of patients to the drug. This trial is being carried out...
Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including melanoma. The main outcomes to be measured are drug toxicity, and response rate of patients to the drug. This trial is being...
Read More
In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...
Read More
In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...
Read More
In a nutshell This trial is evaluating the safety and effectiveness of experimental treatment REGN5093 in patients with advanced non-small-cell lung cancer (NSCLC). The main outcomes to be evaluated will be the number of patients who experience side effects, the maximum dose without significant side effects, and response to treatment. This trial is...
Read More
